Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial
Dr. Vania Hungria presents the Phase 3 DREAMM-7 trial results, demonstrating that belantamab mafodotin, bortezomib, and dexamethasone (BVd) achieved a statistically significant and clinically meaningful overall survival benefit over daratumumab, bortezomib, and dexamethasone (DVd) in relapsed/refractory multiple myeloma, with deep, durable responses and manageable safety outcomes.
Alissa Cooper, MD, reviews new data for established and emerging antibody-drug conjugate targets in non–small cell lung cancer and argues that payload innovation and better patient selection are the field's greatest needs.